行业分析 |
|
|
|
|
靶向蛋白质降解技术发展态势分析* |
施慧琳,李伟,靳晨琦,徐萍,王玥**() |
中国科学院上海营养与健康研究所 中国科学院上海生命科学信息中心 上海 200031 |
|
Analysis of the Development Trend of Targeted Protein Degradation Technology |
SHI Huilin,LI Wei,JIN Chenqi,XU Ping,WANG Yue**() |
Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, China |
引用本文:
施慧琳, 李伟, 靳晨琦, 徐萍, 王玥. 靶向蛋白质降解技术发展态势分析*[J]. 中国生物工程杂志, 2024, 44(2/3): 190-198.
SHI Huilin, LI Wei, JIN Chenqi, XU Ping, WANG Yue. Analysis of the Development Trend of Targeted Protein Degradation Technology. China Biotechnology, 2024, 44(2/3): 190-198.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2305031
或
https://manu60.magtech.com.cn/biotech/CN/Y2024/V44/I2/3/190
|
[1] |
Sakamoto K M, Kim K B, Kumagai A, et al. Protacs:chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98(15): 8554-8559.
|
[2] |
Schneekloth A R, Pucheault M, Tae H S, et al. Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. Bioorganic & Medicinal Chemistry Letters, 2008, 18(22): 5904-5908.
doi: 10.1016/j.bmcl.2008.07.114
|
[3] |
He M, Cao C G, Ni Z H, et al. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduction and Targeted Therapy, 2022, 7: 181.
doi: 10.1038/s41392-022-00999-9
pmid: 35680848
|
[4] |
Donovan K A, Ferguson F M, Bushman J W, et al. Mapping the degradable kinome provides a resource for expedited degrader development. Cell, 2020, 183(6): 1714-1731.e10.
doi: 10.1016/j.cell.2020.10.038
pmid: 33275901
|
[5] |
Schneider M, Radoux C J, Hercules A, et al. The PROTACtable genome. Nature Reviews Drug Discovery, 2021, 20: 789-797.
doi: 10.1038/s41573-021-00245-x
pmid: 34285415
|
[6] |
C4 Therapeutics. C4 therapeutics presents pre-clinical data on CFT8919, a selective degrader of EGFR L858R, at keystone symposium on targeted protein degradation. [2023-04-20]. https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-presents-pre-clinical-data-cft8919-selective.
|
[7] |
Bond M J, Chu L, Nalawansha D A, et al. Targeted degradation of oncogenic KRAS(G12C) by VHL-recruiting PROTACs. ACS Central Science, 2020, 6(8): 1367-1375.
doi: 10.1021/acscentsci.0c00411
|
[8] |
Bond M J, Crews C M. Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation. RSC Chemical Biology, 2021, 2(3): 725-742.
doi: 10.1039/d1cb00011j
pmid: 34212149
|
[9] |
Weagel E G, Foulks J M, Siddiqui A, et al. Molecular glues: enhanced protein-protein interactions and cell proteome editing. Medicinal Chemistry Research, 2022, 31(7): 1068-1087.
doi: 10.1007/s00044-022-02882-2
|
[10] |
Jevtic P, Haakonsen D L, Rapé M, et al. An E3 ligase guide to the galaxy of small-molecule-induced protein degradation. Cell Chemical Biology, 2021, 28(7): 1000-1013.
doi: 10.1016/j.chembiol.2021.04.002
|
[11] |
Lv D W, Pal P, Liu X G, et al. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nature Communications, 2021, 12: 6896.
doi: 10.1038/s41467-021-27210-x
pmid: 34824248
|
[12] |
Imaide S, Riching K M, Makukhin N, et al. Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity. Nature Chemical Biology, 2021, 17: 1157-1167.
doi: 10.1038/s41589-021-00878-4
pmid: 34675414
|
[13] |
Yang Z M, Sun Y H, Ni Z H, et al. Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently. Cell Research, 2021, 31: 1315-1318.
doi: 10.1038/s41422-021-00533-6
pmid: 34417569
|
[14] |
Cotton A D, Nguyen D P, Gramespacher J A, et al. Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1. Journal of the American Chemical Society, 2021, 143(2): 593-598.
doi: 10.1021/jacs.0c10008
pmid: 33395526
|
[15] |
Marei H, Tsai W T K, Kee Y S, et al. Antibody targeting of E3 ubiquitin ligases for receptor degradation. Nature, 2022, 610: 182-189.
doi: 10.1038/s41586-022-05235-6
|
[16] |
Pance K, Gramespacher J A, Byrnes J R, et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins. Nature Biotechnology, 2023, 41: 273-281.
doi: 10.1038/s41587-022-01456-2
|
[17] |
Xue G, Wang K, Zhou D L, et al. Light-induced protein degradation with photocaged PROTACs. Journal of the American Chemical Society, 2019, 141(46): 18370-18374.
doi: 10.1021/jacs.9b06422
pmid: 31566962
|
[18] |
Pfaff P, Samarasinghe K T G, Crews C M, et al. Reversible spatiotemporal control of induced protein degradation by bistable PhotoPROTACs. ACS Central Science, 2019, 5(10): 1682-1690.
doi: 10.1021/acscentsci.9b00713
pmid: 31660436
|
[19] |
Cheng W Y, Li S S, Wen X Q, et al. Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia. Chemical Communications, 2021, 57(95): 12852-12855.
doi: 10.1039/d1cc05715d
pmid: 34788776
|
[20] |
Liang C J, Zheng Q Z, Luo T L, et al. Enzyme-catalyzed activation of pro-PROTAC for cell-selective protein degradation. CCS Chemistry, 2022, 4(12): 3809-3819.
doi: 10.31635/ccschem.022.202101529
|
[21] |
Zhou Y X, Teng P, Montgomery N T, et al. Development of triantennary N-acetylgalactosamine conjugates as degraders for extracellular proteins. ACS Central Science, 2021, 7(3): 499-506.
doi: 10.1021/acscentsci.1c00146
pmid: 33791431
|
[22] |
Liu J, Chen H, Liu Y, et al. Cancer selective target degradation by folate-caged PROTACs. Journal of the American Chemical Society, 2021, 143(19): 7380-7387.
doi: 10.1021/jacs.1c00451
pmid: 33970635
|
[23] |
Gao J, Hou B, Zhu Q W, et al. Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy. Nature Communications, 2022, 13: 4318.
doi: 10.1038/s41467-022-32050-4
pmid: 35882867
|
[24] |
He S P, Gao F, Ma J H, et al. Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer. Angewandte Chemie (International Ed in English), 2021, 60(43): 23299-23305.
doi: 10.1002/anie.v60.43
|
[25] |
Ahn G, Banik S M, Miller C L, et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nature Chemical Biology, 2021, 17: 937-946.
doi: 10.1038/s41589-021-00770-1
pmid: 33767387
|
[26] |
Morreale F E, Kleine S, Leodolter J, et al. BacPROTACs mediate targeted protein degradation in bacteria. Cell, 2022, 185(13): 2338-2353.e18.
doi: 10.1016/j.cell.2022.05.009
pmid: 35662409
|
[27] |
刘少金, 窦树珍, 王俊姝, 等. 靶向蛋白降解药物市场分析及建议. 中国生物工程杂志, 2023, 43(S1): 190-200.
|
|
Liu S J, Dou S Z, Wang J S, et al. Market analysis and suggestions of targeted protein degradation drugs. China Biotechnology, 2023, 43(S1): 190-200.
|
[28] |
Zheng S J, Tan Y H, Wang Z Y, et al. Accelerated rational PROTAC design via deep learning and molecular simulations. Nature Machine Intelligence, 2022, 4: 739-748.
doi: 10.1038/s42256-022-00527-y
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|